Oral squamous cell carcinoma (OSCC) is a common human malignancy with high incidence rate and poor prognosis. Although the polycomb group protein enhancer of zeste homolog 2 (EZH2) plays a crucial role in cell proliferation and differentiation during the occurrence and development progress of several kinds of malignant tumors, the impact of EZH2 on the development and progression of OSCC is unclear. In this study, we demonstrate that EZH2 is overexpressed in OSCC cells and clinical tissue. With in vitro RNAi analysis, we generated stable EZH2 knocking down cell lines from two OSCC cell lines, with two sh-RNAs targeting to EZH2, respectively. We found that knocking down of EZH2 could decrease the proliferation ability and induce apoptosis of OSCC cells. Moreover, we demonstrated that of EZH2 inhibition decreased the migration and metastasis of OSCC cells. In conclusion, the results of the current study demonstrated an association between EZH2 expression and OSCC cell development. We recommend that EZH2 acts as an oncogene and plays an important role in OSCC carcinogenesis.
Keywords: DMEM; Dulbecco's modified Eagle's medium; EGFR; EZH2; FBS; GAPDH; H3K27; HNSCC; OSCC; Oncogene; Oral squamous cell carcinoma; PVDF; a specific histone 3 lysine 27; enhancer of zeste homolog 2; epithelial growth factor receptor; fetal bovine serum; glyceraldehyde-3-phosphate dehydrogenase; head and neck squamous cell carcinoma; oral squamous cell carcinoma; polyvinylidene difluoride; qRT-PCR; quantitative reverse transcription polymerase chain reaction.
Copyright © 2014 Elsevier B.V. All rights reserved.